Xenon to Present at Upcoming Investor Conferences
Xenon Pharmaceuticals (Nasdaq: XENE) will present at two investor conferences in November 2025: the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025 at 3:20 PM ET and the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 11:30 AM GMT / 6:30 AM ET. Webcasts are mentioned and will be posted for replay when available. Dates and times are subject to change.
The release reiterates Xenon’s focus on neuroscience drug discovery and development, notes lead molecule azetukalner is in Phase 3 for epilepsy, MDD and BPD, and references Phase 1 programs for Nav1.7 and Kv7 targeting pain. Investor materials and webcast links will be available on Xenon’s Investors webpage.
Xenon Pharmaceuticals (Nasdaq: XENE) parteciperà a due conferenze per investitori nel novembre 2025: la Stifel 2025 Healthcare Conference il giovedì 13 novembre 2025 alle 15:20 ET e la Jefferies Global Healthcare Conference a Londra il mercoledì 19 novembre 2025 alle 11:30 GMT / 6:30 ET. Le webcast sono menzionate e verranno pubblicate per la riproduzione quando disponibili. Le date e gli orari sono soggetti a modifiche.
Il comunicato ribadisce l'attenzione di Xenon sulla scoperta e lo sviluppo di farmaci per il sistema nervoso centrale, segnala che la molecola principale azetukalner è in Fase 3 per epilessia, MDD e BPD, e fa riferimento a programmi di Fase 1 per Nav1.7 e Kv7 mirati al dolore. I materiali per gli investitori e i link alle webcast saranno disponibili sulla pagina degli Investitori di Xenon.
Xenon Pharmaceuticals (Nasdaq: XENE) presentará en dos conferencias para inversionistas en noviembre de 2025: la Conferencia de Salud de Stifel 2025 el jueves 13 de noviembre de 2025 a las 3:20 PM ET y la Conferencia Global de Salud de Jefferies en Londres el miércoles 19 de noviembre de 2025 a las 11:30 AM GMT / 6:30 AM ET. Se mencionan webcast y se publicarán para su reproducción cuando estén disponibles. Las fechas y horas están sujetas a cambios.
El comunicado reitera el enfoque de Xenon en el descubrimiento y desarrollo de fármacos para neurociencia, señala que la molécula principal azetukalner está en Fase 3 para epilepsia, MDD y BPD, y hace referencia a programas de Fase 1 para Nav1.7 y Kv7 orientados al dolor. Los materiales para inversionistas y los enlaces a webcast estarán disponibles en la página de Inversores de Xenon.
Xenon Pharmaceuticals (Nasdaq: XENE)은 2025년 11월 두 차례의 투자자 컨퍼런스에서 발표할 예정입니다: Stifel 2025 Healthcare Conference는 2025년 11월 13일 목요일 오후 3:20 ET에, Jefferies Global Healthcare Conference는 런던에서 2025년 11월 19일 수요일 11:30 GMT / 6:30 AM ET에 개최됩니다. 웹캐스트가 언급되었고 가능할 때 재생용으로 게시됩니다. 날짜와 시간은 변경될 수 있습니다.
보도자료는 Xenon의 신경과학 약물 발견 및 개발에 대한 집중을 재확인하고, 주력 분자 azetukalner가 간질, 주요 우울 장애(MDD), 양극성 장애(BPD)에 대해 3상에 있으며, 통증을 목표로 하는 Nav1.7 및 Kv7의 1상 프로그램을 언급합니다. 투자자 자료와 웹캐스트 링크는 Xenon의 투자자 페이지에서 이용 가능할 예정입니다.
Xenon Pharmaceuticals (Nasdaq: XENE) participera à deux conférences investisseurs en novembre 2025 : la Stifel 2025 Healthcare Conference le jeudi 13 novembre 2025 à 15h20 ET et la Jefferies Global Healthcare Conference à Londres le mercredi 19 novembre 2025 à 11h30 GMT / 6h30 ET. Des webcasts sont mentionnés et seront mis en ligne pour replay lorsque disponibles. Les dates et heures peuvent changer.
Le communiqué réaffirme l’orientation de Xenon vers la découverte et le développement de médicaments en neurosciences, indique que la molécule principale azetukalner est en phase 3 pour l’épilepsie, le TMD et le trouble bipolaire (BPD), et fait référence à des programmes de phase 1 pour Nav1.7 et Kv7 ciblant la douleur. Le matériel destiné aux investisseurs et les liens vers les webcasts seront disponibles sur la page Investisseurs de Xenon.
Xenon Pharmaceuticals (Nasdaq: XENE) wird im November 2025 bei zwei Investorenkonferenzen präsentieren: die Stifel 2025 Healthcare Conference am Donnerstag, 13. November 2025 um 15:20 Uhr ET und die Jefferies Global Healthcare Conference in London am Mittwoch, 19. November 2025 um 11:30 Uhr GMT / 6:30 Uhr ET. Webcasts werden erwähnt und stehen zur Wiederholung zur Verfügung, sobald sie verfügbar sind. Daten und Uhrzeiten können sich ändern.
Die Mitteilung bekräftigt Xenons Fokus auf Entdeckung und Entwicklung von Medikamenten im Bereich der Neurowissenschaften, vermerkt, dass die Leitsubstanz azetukalner sich in Phase 3 für Epilepsie, MDD und BPD befindet, und verweist auf Phase-1-Programme für Nav1.7 und Kv7, die Schmerz behandeln. Investorenmaterialien und Webcast-Links werden auf der Xenon-Investorenwebseite verfügbar sein.
Xenon Pharmaceuticals (Nasdaq: XENE) ستقدم في مؤتمرين للمستثمرين في نوفمبر 2025: مؤتمر ستيفل للرعاية الصحية 2025 في الخميس 13 نوفمبر 2025 الساعة 3:20 مساءً بتوقيت شرق الولايات المتحدة ET ومؤتمر Jefferies العالمي للرعاية الصحية في لندن يوم الأربعاء 19 نوفمبر 2025 الساعة 11:30 صباحاً GMT / 6:30 صباحاً ET. ستذكر البثوث المباشرة وسيتم نشرها لإعادة المشاهدة عند التوفر. التواريخ والأوقات قابلة للتغيير.
يؤكد البيان تركيز Xenon على اكتشاف وتطوير أدوية الأعصاب، ويشير إلى أن الجزيء الرئيسي azetukalner في المرحلة 3 لعلاج الصرع واضطراب ما بعد الصدمة؟ لندعها كما هي: Epilepsy، MDD و BPD، ويشير إلى برامج المرحلة 1 لـ Nav1.7 و Kv7 المستهدفة للألم. المواد المخصصة للمستثمرين وروابط البث ستكون متاحة على صفحة المستثمرين في Xenon.
- None.
- None.
VANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the Company will present at two upcoming investor conferences.
- Stifel 2025 Healthcare Conference
Thursday, November 13, 2025 at 3:20 PM ET
Webcast link here
- Jefferies Global Healthcare Conference in London on
Wednesday, November 19, 2025 at 11:30 AM GMT/6:30 AM ET
Webcast link here
Details about company presentations, webcasts, and other events can be found on the Investors section of Xenon's website. When available, webcasts will be posted for replay following the event. The above-listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical studies for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Nav1.7 and Kv7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contact:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
Media: media@xenon-pharma.com
Investors: investors@xenon-pharma.com
FAQ
When will Xenon (XENE) present at the Stifel 2025 Healthcare Conference?
When and where is Xenon (XENE) presenting at the Jefferies Global Healthcare Conference?
Will Xenon (XENE) provide webcasts of its November 2025 conference presentations?
Where can investors find Xenon (XENE) presentation details and replays from November 2025?
What pipeline updates does Xenon (XENE) reference in the November 6, 2025 announcement?
